Recursion Pharmaceuticals (RXRX) Intangibles (2020 - 2025)
Historic Intangibles for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $322.3 million.
- Recursion Pharmaceuticals' Intangibles rose 84548.44% to $322.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $322.3 million, marking a year-over-year increase of 84548.44%. This contributed to the annual value of $335.9 million for FY2024, which is 82158.99% up from last year.
- Latest data reveals that Recursion Pharmaceuticals reported Intangibles of $322.3 million as of Q3 2025, which was up 84548.44% from $341.3 million recorded in Q2 2025.
- Recursion Pharmaceuticals' Intangibles' 5-year high stood at $341.3 million during Q2 2025, with a 5-year trough of $1.2 million in Q2 2022.
- For the 5-year period, Recursion Pharmaceuticals' Intangibles averaged around $98.0 million, with its median value being $35.3 million (2023).
- Per our database at Business Quant, Recursion Pharmaceuticals' Intangibles plummeted by 1799.88% in 2021 and then surged by 336772.1% in 2023.
- Recursion Pharmaceuticals' Intangibles (Quarter) stood at $1.4 million in 2021, then fell by 5.7% to $1.3 million in 2022, then skyrocketed by 2690.43% to $36.4 million in 2023, then soared by 821.59% to $335.9 million in 2024, then fell by 4.02% to $322.3 million in 2025.
- Its Intangibles was $322.3 million in Q3 2025, compared to $341.3 million in Q2 2025 and $335.8 million in Q1 2025.